GlassScriptPhysician profile
Ingrid C Encinas
NPI 1447766480
$7,135.72
in general payments reported to CMS, 2019-2025
23 companies · $1,154 in 2025
The $1,154 reported for 2025 was more than what 83% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,785 · 2022: $2,986 · 2023: $1,133 · 2024: $77.54 · 2025: $1,154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,365.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,416.63 | 2021-2025 | |
| Alkermes, INC. | $1,205.46 | 2021-2025 | Lybalvi, Aristada, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $750.09 | 2021-2025 | Rexulti, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $682.49 | 2021-2025 | Austedo Xr, Austedo |
| Janssen Pharmaceuticals, INC | $606.42 | 2021-2023 | Invega Sustenna, Invega Trinza |
| Axsome Therapeutics, INC. | $480.08 | 2022-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $462.56 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $264.90 | 2022-2025 | |
| Sunovion Pharmaceuticals INC. | $195.58 | 2021-2022 | |
| Lundbeck LLC | $175.08 | 2022-2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $120.93 | 2021-2023 | Jornay Pm |
| Livanova USA, INC. | $120.16 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $117.72 | 2022-2023 | Trintellix |
| Vanda Pharmaceuticals INC. | $107.23 | 2022 | |
| Corium, LLC | $86.79 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $75.59 | 2022-2023 | Qelbree |
| E.R. Squibb & Sons, L.L.C. | $57.75 | 2025 | Cobenfy |
| Indivior INC. | $52.57 | 2022-2023 | Perseris |
| Noven Therapeutics, LLC | $45.28 | 2022 | |
| Idorsia Pharmaceuticals US INC | $37.07 | 2022-2023 | Quviviq |
| Janssen Scientific Affairs, LLC | $34.04 | 2025 | Invega Sustenna |
| Acadia Pharmaceuticals INC | $25.92 | 2025 | Nuplazid |
| Alfasigma USA, INC. | $15.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ingrid Encinas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.